Kaplan Fox Reminds Erasca, Inc. (ERAS) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 10, 2026

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) on behalf of investors that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026 (the "Class Period").

If you are an investor in Erasca and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 10, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

According to the complaint, on April 27, 2026, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed") alleging that Erasca's ERAS-0015 infringes a RevMed patent and is connected to alleged trade secret misappropriation. Further, according to the complaint, RevMed also alleged that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures" and demanded Erasca cease making "deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236." The Company has stated that it believes the assertions are without merit and intends to contest the allegations.

On this news, the price of Erasca stock fell $2.34 per share, nearly 11%, to close at $19.15 per share on April 27, 2026.

The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) ERAS-0015's preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.